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48.2 ± 19.3 mmHg, and tricuspid regurgitation pressure gradient
(TRPG) 57.5 ± 25.2 mmHg. Pericardial effusion was observed in 28%.
ERA, prostacyclin, PDE-5 inhibitor and epoprostenolwere used in 71.8%,
60.9%, 51.8%, and 18.2%, respectively. There were no signiﬁcant
difference in characteristics between the monotherapy group and the
combination therapy group, except for the frequent use of the
combination therapy in idiopathic PAH. Although pericardial effusion,
cardiac index, and mean right atrial pressure were predictors for
mortality in the combination group, there was no difference in
mortality between themonotherapy group and the combination group.
Conclusion: Combination therapy was frequently used in idiopathic
PAH. However, difference in mortality was not apparent between
monotherapy and combination therapy with other PAH drugs.
doi:10.1016/j.lfs.2013.12.161
Clinical effect of ambrisentan in pulmonary hypertension
Toshinori Minamishima, Toru Satoh, Masaharu Kataoka, Hideaki Yoshino
Cardiology Division, Department of Medicine, Kyorin University School of
Medicine, Japan
E-mail address: tsatoh2008@me.com (T. Satoh)
Background: A development of the drugs used in pulmonary
hypertension (PH) contributes a lot to its clinical improvement. An
advent of new endothelin receptor blocker, ambrisentan, has further
diversiﬁed selection of PH drugs. Purpose: The purpose of this study
was to evaluate the efﬁcacy and safety of ambrisentan on PH. Method:
Ambrisentan was administered to 26 (50 ± 19 years old, 7 men, 19
women) patients with PH including 11 patients with chronic throm-
boembolic PH (CTEPH), 5 with Eisenmenger syndrome, 5 with
connective tissue disease (CTD) PH and 3 with idiopathic pulmonary
arterial hypertension. Ambrisentan was added to the other PH drugs in
all the patients. The patients underwent right-side heart catheterization
before and after the administration of ambrisentan with measurement
of cardiac output (CO), mean right atrial pressure (mRA), mean
pulmonary arterial pressure (mPA), pulmonary vascular resistance
(PVR). Brain natriuretic peptide (BNP) was also determined. Results:
After administration of ambrisentan (the average follow-up period was
168 ± 97 days), mPA (36 ± 9 vs 22± 6: p b 0.01) and PVR (11 ± 6 vs.
7 ± 4: p b 0.01) and CO (4.0 ± 1.5 vs. 4.8 ± 1.8: p b 0.05) improved
signiﬁcantly, but BNP, mRA nor heart rate did not. The most frequent
adverse reactions was edema with 6 patients, 3 of which abandoned
ambrisentan. Conclusions: Ambrisentan is useful for pulmonary
hypertension even if added to other PH drugs.
doi:10.1016/j.lfs.2013.12.162
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Introduction: Chronic thromboembolic pulmonary hypertension
(CTEPH) is a serious devastating disease. It is still a challenge to treat
some patients who are not eligible for pulmonary endarterectomy.
Short-term bosentan or PDE5 inhibitor was signiﬁcantly improved in
symptoms, hemodynamics and exercise capacity in such patients.
However, the long-term beneﬁcial effect of advanced pulmonary
vasodilating drugs is little understood. Therefore, we investigated the
long-term effect of advanced therapy in the patients with inoperable
CTEPH retrospectively. Methods and results: All consecutive 7 Japanese
patients (5 female, mean age 62.6 ± 6.9 years) treated with bosentan
(125–250 mg) for symptomatic inoperable CTEPH were included. The
time to clinicalworsening (TCW)was examined (mean follow-up period
896 ± 564 days). WHO-FC was signiﬁcantly improved from 3.1 ± 0.4 to
2.1 ± 0.4 (p b 0.01). Pulmonary vascular resistance was signiﬁcantly
decreased from 786.9 ± 300.0 to 352.2 ± 210.7 dyn s cm−5 (p b 0.05).
Mean pulmonary artery pressure and cardiac index were improved
from 47.0 ± 7.6 to 43.3 ± 5.0 mmHg and from 2.18 ± 0.39 to 3.02 ±
0.74 l/min/m2 (n= 3, follow-up 651–849 days). Six-minute walk dis-
tance was increased from 257.0 ± 151.0 to 369.8 ± 85.7 m (p= 0.06,
n = 4, follow-up 651–931 days). Plasma BNP level was signiﬁcantly
decreased from 1160.0 ± 971.4 to 305.1 ± 285.9 pg/ml (p b 0.05). None
of themwere required hospitalization. Conclusions: Long-term advanced
therapy with bosentan improves symptoms, hemodynamics and TCW in
CTEPH patients. Advanced therapy is proposed as an essential treatment
for the patients with inoperable CTEPH.
doi:10.1016/j.lfs.2013.12.163
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Background: A recently developed mouse model for PAH combines
hypoxia with a VEGF receptor blocker. Herein we aim to describe in
detail this model. The TGFβ/Smad3 pathway is a pivotal factor
regulating the transcription of the endothelin (ET-1) gene. Besides,
interleukin-1β (IL-1β) increases expression of ET-1, and ETA receptor
and reduces expression of ETB receptor. Methods and results: We
placed 3-week old male SV129 mice under hypoxia (O2 = 10%) and
treated themwith a vascular endothelial growth factor receptor blocker
(SU5416) (SU mice) (subcutaneous injection three times a week,
20 mg/kg) for 3 weeks. Compared tomice under hypoxia alone (H) and
control mice (CTRL), these mice developed severe PAH, characterized
by increased right ventricular systolic pressure measured in anesthe-
tized mice by subxiphoid approach (SU: 37 ± 1.7; H: 29 ± 1.4,
CTRL: 22.5 ± 1mmHg), right ventricularhypertrophy (Fulton index: SU:
0.55 ± 0.042; H: 0.4 ± 0.04, CTRL:0.31 ± 0.026) and muscularization
of precapillary vessels together with proliferation of endothelial cells
of small arterioles (PCNA positive on endothelial layer/arterial
section = SU: 2.9 ± 0.25; H: 1 ± 0.13; CTRL: 0.7 ± 0.08), which
lead to completely occluded arterioles by von Willebrand factor
expressing cells. Increased ET-1 mRNA, ETA receptor mRNA, protein
expression and immunostaining signals and reduced ETB receptor
mRNA expression were observed in SU mice only. This was
associated with an increased abundance of phosphorylated Smad3
and a 9-fold increase of IL-1β expression. TGF-β mRNA in H and SU
mice was similar. Conclusion: In severe PAH, Smad3 by potentiating
TGF-β and IL-1β might disturb the expression of the ET system and
may represent therefore potential therapeutic targets.
doi:10.1016/j.lfs.2013.12.164
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